Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 150-160

  Zhang, Xin ^a,c   Jones, David R ^b   Hall, Stephen D ^b,c  

^a PURDUE UNIVERSITY   (United States)

^b Indiana University   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; N NORDILTIAZEM; N NORERYTHROMYCIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DILTIAZEM; ENZYME INHIBITORS; ERYTHROMYCIN; HUMANS; MICROSOMES, LIVER; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 58149464706     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022178     Document Type: Article

References (22)

1. Backman JT, Olkkola KT, Arauko K, Himberg JJ, and Neuvonen PJ (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221-225.
2. Dennison JB, Jones DR, Renbarger JL, and Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563.
3. Food and Drug Administration, U.S. Department of Health and Human Services: Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies: Study Design, Data Analysis, and Recommendations for Dosing and Labeling. September 2006 [Online]. Available: htrp://www.fda.gov/cder November 2006.
4. Gandhi TK, Weingart SN, Boms J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, et al. (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556-1564.
5. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
6. Gorski JC, Hall SD, Jones DR, VaudenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
7. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
8. Ito K, Ogihara K, Kanamitsu S, and Ltoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954.
9. Jankel CA and Fitterman LK (1993) Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 9:51-59.
10. Lazarou J, Pomeranz B, and Corey P (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:200-1205.
11. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
12. McConn DJ 2nd, Lin YS, Allen K, Kunze KL, and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083-1091.
13. McGinnity DF, Berry AJ, Kenny JR, Grime K, and Riley RJ (2006) Evaluation of timedependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291-1300.
14. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
15. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
16. Olkkola KT, Arauko K, Luurila H, Hiller A, Saaruivaara L, Himberg JJ, and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Phaimacol Ther. 53:298-305.
17. Silverman R (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzyniology. CRC Press, Boca Raton, FL.
18. Yang J, Jamei M, Yeo KR, Tucker GT, and Rostami-Hodjegan A (2005) Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci 26:334-340.
19. Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, and Marroum P (1999) In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther 66:9-15.
20. Zhao P. Kunze KL, and Lee CA (2005) Evaluation of time-dependent inactivation of CYP3 A in cryopreserved human hepatocytes. Drug Metab Dispos 33:853-861.
21. Zhao XJ, Jones DR, Wang YH, Grimm SW, and Hall SD (2002) Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32:863-878.
22. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, and Xu A (2004) Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415-442.